Thrombosis, cancer and renal insufficiency: Low molecular weight heparin at the crossroads

Supportive Care in Cancer

Volumn 20, Issue 12, 2012, Pages 3033-3042

  Scotte F ^a   Rey, J B ^b   Launay Vacher, V ^c  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b INSTITUT JEAN GODINOT   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cancer; Kidney disease; Low molecular weight heparin; Prevention; Renal insufficiency; Venous Thromboembolism

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN; WARFARIN;

ACUTE KIDNEY FAILURE; ANTICOAGULANT THERAPY; BLEEDING; CANCER PATIENT; CATHETER REMOVAL; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CHRONIC KIDNEY FAILURE; COMPRESSION STOCKING; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; KIDNEY FAILURE; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; NEOPLASM; PREVALENCE; PRIORITY JOURNAL; REVIEW; THROMBOPLASTIN TIME; THROMBOSIS; THROMBOSIS PREVENTION; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; VENOUS THROMBOEMBOLISM;

EID: 84868455515     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1590-9     Document Type: Review

References (67)

1. Lyman GH (2011) Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 117:1334-1349
2. Verso M, Agnelli G (2003) Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21:3665-3675
3. Farge D, Durant C, Villiers S, Long A, Groupe Francophone Thrombose Cancer (GFTC) et al (2010) Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients. Thromb Res 125(Suppl 2):S108-S116
4. Pruemer J (2005) Prevalence, causes, and impact of cancer-associated thrombosis. Am J Health Syst Pharm 62(22 Suppl 5):S4-S6
5. Launay-Vacher V, Oudard S, Janus N, Renal Insufficiency and Cancer Medications (IRMA) Study Group et al (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 110:1376-1384
6. Givens ML, Wethern J (2009) Renal complications in oncologic patients. Emerg Med Clin North Am 27:283-291
7. Cengiz K (2002) Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol 33:121-126
8. Heit JA, O'Fallon WM, Petterson TM et al (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162:1245-1248
9. Richard H, White MD (2003) The epidemiology of venous thromboembolism. Circulation 107:1-4
10. Khorana AA, Francis CW, Culakova E et al (2007) Risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110:2339-2346
11. Heit JA, Silverstein MD, Mohr DN et al (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a populationbased case-control study. Arch Intern Med 160:809-815
12. Wun T, White RH (2009) Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haematol 22:9-23
13. Karimi M, Cohan N (2010) Cancer-associated thrombosis. Open Cardiovasc Med J 4:78-82
14. Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):381S-453SS
15. Kearon C, Kahn SR, Agnelli G et al (2008) Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 13(6 Suppl):454S-545SS
16. Lyman GH, Khorana AA, Falanga A et al (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490-5505
17. Venous thromboembolic disease NCCN guidelines V2.2009. http://www.nccn.org/professionals/physician-gls/PDF/vte.pdf (Accessed on 21/12/10))
18. Khorana AA (2007) The NCCN clinical practice guidelines on thromboembolic disease: strategies for improving VTE prophylaxis in hospitalized cancer patients. Oncologist 12:1361-1370
19. Mandala M, Falanga A, Piccioli A et al (2006) Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 59:194-204
20. Mandala M, Falanga A, Roila F (2009) Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 20(Suppl 4):182-184
21. Farge D, Bosquet L, Kassab-Chahmi D et al. (2008) SOR French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group. Crit Rev Oncol Hematol 2010(73):31-46..
22. Debourdeau P, Kassab Chahmi D, Le Gal G et al. (2008) SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol 2009(20):1459-1471..
23. Abad Rico JI, Llau Pitarch JV, Páramo Fernández JA (2010) Topical issues in venous thromboembolism. Drugs 70(S2):11-18
24. van Dongen CJ, MacGillavry MR, Prins MH. Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD003074. doi:10.1002/14651858.CD003074.pub2..
25. Noble SI, Finlay IG (2005) Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med 19:197-201
26. Burleigh E, Wang C, Foster D et al (2006) Thromboprophylaxis in medically ill patients at risk for venous thromboembolism. Am J Health Syst Pharm 63(suppl 6):523-529
27. Petersen LJ (2009) Anticoagulation therapy for prevention and treatment of venous thrombolic events in cancer patients: a review of current guidelines. Cancer Treat Revs 35:754-764
28. Cohen AT, Tapson VF, Bergmann JF, ENDORSE Investigators et al (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371:387-394
29. Monreal M, Falgá C, Valdés M, Riete Investigators et al (2006) Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 4:1950-1956
30. Kucher N, Spirk D, Kalka C et al (2008) Clinical predictors of prophylaxis use prior to the onset of acute venous thromboembolism in hospitalized patients SWIss Venous ThromboEmbolism Registry (SWIVTER). J Thromb Haemost 6:2082-2087
31. Matas AJ, Simmons RL, Kjellstrand CM et al (1975) Increased incidence of malignancy during chronic renal failure. Lancet 1:883-886
32. Sutherland GA, Glass J, Gabriel R (1977) Increased incidence of malignancy in chronic renal failure. Nephron 18:182-184
33. Digenis G, Pierratos A, Oreopoulos DG (1986) Cancer and chronic renal failure. CMAJ 135:14-16
34. Peces R (2003) Malignancy and chronic renal failure. Saudi J Kidney Dis Transpl 14:5-14
35. Kjellstrand CM (1979) Are malignancies increased in uremia? Nephron 23:159-161
36. Launay-Vacher V, Etessami R, Renal Insufficiency Anticancer Medications (IRMA) Study Group et al (2009) Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung 187:69-74
37. Launay-Vacher V, Gligorov J, Le Tourneau C, Renal Insufficiency and Anticancer Medications (IRMA) Study Group et al (2010) Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat 124:745-753
38. Launay-Vacher V, Ayllon J, Janus N, Renal Insufficiency and Anticancer Medications (IRMA) Study Group et al (2009) Drug management of prostate cancer: prevalence and consequences of renal insufficiency. Clin Genitourin Cancer 7:E83-E89
39. Darmon M, Ciroldi M, Thiery G et al (2006) Clinical review: specific aspects of acute renal failure in cancer patients. Crit Care 10:211
40. Launay-Vacher V, Janus N, Spano JP et al. (2009) Impact of renal insufficiency on cancer survival: results of the IRMA-2 study. ASCO Annual Meeting 2009. Abstract 9585. J Clin Oncol. 27: 15S (Suppl; abstr 9585))
41. Launay-Vacher V (2010) Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol 30:548-556
42. Stenvinkel P (2010) Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med 268:456-467
43. Janus N, Launay-Vacher V, Byloos E et al (2010) Cancer and renal insufficiency results of the BIRMA study. Br J Cancer 103:1815-1821
44. Kleber M, Cybulla M, Bauchmüller K et al (2007) Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice. Ann Oncol 18:950-958
45. Levey AS, Bosch JP, Lewis JB, Modification of Diet in Renal Disease Study Group et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461-470
46. Levey AS, Greene T, Kusek JW et al (2000) A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol 11:0828
47. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(suppl 1):S1-S266
48. Levey AS, Coresh J, Balk E, National Kidney Foundation et al (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137-147
49. Schmid P, Fischer AG, Wuillemin WA (2009) Low-molecularweight heparin in patients with renal insufficiency. Swiss Med Wkly 139:438-452
50. Hulot JS, Montalescot G, Lechat P et al (2005) Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 77:542-552
51. Crowther M, Lim W (2007) Low molecular weight heparin and bleeding in patients with chronic renal failure. Curr Opin Pulm Med 13:409-413
52. Sanderink GJ, Guimart CG, Ozoux ML et al (2002) Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 105:225-231
53. Mahé I, Aghassarian M, Drouet L et al (2007) Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 97:581-586
54. Gerlach AT, Pickworth KK, Seth SK et al (2000) Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 20:771-775
55. Busby LT, Weyman A, Rodgers GM (2001) Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am J Hematol 67:54-56
56. Lim W, Dentali F, Eikelboom JW, Crowther MA (2006) Metaanalysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144:673-684
57. Becker RC, Spencer FA, Gibson M, TIMI 11A Investigators et al (2002) Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 143:753-759
58. Cheer SM, Dunn CJ, Foster R (2004) Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease. Drugs 64:1479-1502
59. Kessler CM (2009) The link between cancer and venous thromboembolism: a review. Am J Clin Oncol 32(4 Suppl):S3-S7
60. White RH, Chew H, Wun T (2007) Targeting patients for anticoagulant prophylaxis trials in patients with cancer: who is at highest risk? Thromb Res 120(Suppl 2):S29-S40
61. Zangari M, Fink LM, Elice F et al (2009) Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 27:4865-4873
62. Khorana AA, Francis CW, Blumberg N et al (2008) Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 168:2377-2381
63. www.rxlist.com [last accessed 22/11/11]
64. www.rxmed.com [last accessed 22/11/11]
65. www.sor-cancer.fr [last accessed 14/3/11]
66. www.e-cancer.fr [last accessed 14/3/11]
67. Eriksson BI, Söderberg K, Widlund L et al (1995) A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 73:398-401